Andrea Sabens Sells 341 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $61.24, for a total transaction of $20,882.84. Following the completion of the sale, the chief accounting officer now directly owns 63,239 shares in the company, valued at $3,872,756.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Andrea Sabens also recently made the following trade(s):

• On Tuesday, February 13th, Andrea Sabens sold 341 shares of Lantheus stock. The shares were sold at an average price of $55.31, for a total transaction of $18,860.71.

Lantheus Trading Down 0.4 %

Shares of NASDAQ LNTH traded down $0.25 during mid-day trading on Wednesday, hitting $61.48. The stock had a trading volume of 536,995 shares, compared to its average volume of 1,059,682. The business has a 50 day moving average price of $60.39 and a two-hundred day moving average price of $63.01. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $100.85. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The firm has a market cap of $4.21 billion, a P/E ratio of 13.48 and a beta of 0.53.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The company had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Macquarie Group Ltd. raised its holdings in Lantheus by 21.7% during the 1st quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 108 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in Lantheus by 36.6% during the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 156 shares during the last quarter. RFG Advisory LLC raised its holdings in Lantheus by 4.4% during the 3rd quarter. RFG Advisory LLC now owns 3,940 shares of the medical equipment provider’s stock valued at $274,000 after buying an additional 167 shares during the last quarter. Prosperity Financial Group Inc. raised its holdings in Lantheus by 6.2% in the 3rd quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 173 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Lantheus by 3.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock worth $432,000 after purchasing an additional 188 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LNTH has been the topic of a number of recent analyst reports. B. Riley lowered their target price on shares of Lantheus from $113.00 to $95.00 and set a “buy” rating on the stock in a research note on Wednesday, January 10th. Truist Financial reissued a “buy” rating and set a $82.00 price target (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. JMP Securities reissued a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. Finally, StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.14.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.